Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00129350|
Recruitment Status : Unknown
Verified August 2005 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : August 11, 2005
Last Update Posted : September 7, 2005
At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes. The programmes operate under evidence-based guidelines as outlined by the Chartered Society of Physiotherapy. Increasing evidence shows that rehabilitation programmes help improve performance, exercise endurance, and quality of life; and reduce symptoms and demand on health-care resources. This study proposes to compare the outcomes of lung and heart-lung transplant patients attending local pulmonary rehabilitation against others receiving the Trust's current document-based programme. The study is a randomized controlled trial:
- Control Arm: Those patients randomized to the 'control' arm will receive the Trust's standard rehabilitation programme that consists of an information pack supplied upon discharge. They will then complete and undertake the following tests: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). The patient will follow the information contained in the information pack and the above tests and questionnaires will be repeated 6 months post discharge.
- Experimental Arm: A patient who is randomized to the 'experimental' arm will be asked to complete the following tests upon discharge: Short-Form 36 (SF 36; version 2) Questionnaire, Chronic Respiratory Questionnaire (CRQ-SR), Incremental Shuttle Walk Test and Spirometry FEV1 and FVC. Three months post discharge, the patient will be enrolled into a local pulmonary rehabilitation programme. The programme is typically structured to last 6-12 weeks. The above tests and questionnaires will be repeated 6 months post discharge.
To measure the effectiveness of either the information pack or the rehabilitation programme the following endpoints will be subjected to analysis in both the experimental and the control group:
- Short-Form 36 Questionnaire;
- Chronic Respiratory Questionnaire;
- Incremental Shuttle Walk Test;
- Borg Scale;
- Spirometry FEV1 and FVC;
- Hospital re-admission rates and mortality rates.
The undertaking of a multidisciplinary-led programme of rehabilitation facilitates a better quality of life than a document-based rehabilitation programme in lung and or heart-lung transplant out-patients.
The aim of the study is to construct an optimal programme of rehabilitation in lung or heart-lung patients.
|Condition or disease||Intervention/treatment||Phase|
|Emphysema Alveolitis, Fibrosing Cystic Fibrosis Bronchiectasis Lung Diseases||Procedure: Pulmonary rehabilitation programme||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Assessment of Patient Outcomes Following a Rehabilitation Programme for Patients Who Have Received Lung or Heart-Lung Transplant - a Randomised Controlled Trial|
|Study Start Date :||September 2004|
|Study Completion Date :||February 2008|
- Exercise Shuttle Test (metres completed)
- Borg score
- Quality of life: SF-36 and Chronic Respiratory Questionnaires
- Hospital re-admission rates
- Organ rejection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129350
|Contact: MICHAEL G PREEDY, BSc Econ||02073528121 ext 2172||M.Preedy@rbh.nthames.nhs.uk|
|Contact: CHRISTOPHER THEAKER||02073528121 ext 8464||C.Theaker@rbh.nthames.nhs.uk|
|Harefield, United Kingdom, UB96JH|
|Principal Investigator: MICHAEL G PREEDY, BScEcon|
|Principal Investigator:||MARTIN CARBY||Royal Brompton & Harefield NHS Foundation Trust|